Consequently, there is a lack of efficient target therapy options against EGFR ex20in NSCLC as EGFR‐TKIs are not a recommended treatment option according to current treatment guidelines in Japan.12 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.